Publications by authors named "P L Weiden"
Article Synopsis
- Aripiprazole lauroxil (AL) is a long-acting injectable antipsychotic that can be initiated using either a 1-day or 21-day regimen, and this study analyzed their safety and tolerability.
- The post hoc analysis showed comparable adverse event rates between both regimens, with most events being mild, although some specific side effects (like injection site reactions and akathisia) were noted.
- The findings indicate that both initiation approaches are similarly safe, suggesting the importance of involving patients in selecting their treatment plan for schizophrenia.
Article Synopsis
- - KarXT, a combination of xanomeline and trospium, showed effectiveness and tolerability in treating schizophrenia in the EMERGENT-1 study, hitting its primary and secondary goals while being well tolerated overall.
- - The study involved 179 patients who either received KarXT or a placebo, revealing that the majority of side effects (like nausea and dry mouth) were mild and temporary, with no participants dropping out due to these issues.
- - Additionally, KarXT did not significantly affect body weight, metabolic parameters, or vital signs, confirming its safety profile in relation to the muscarinic activity of its components.
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.
Trends Pharmacol Sci
December 2022
Article Synopsis
- Interest in muscarinic acetylcholine receptor (mAChR) activators for schizophrenia surged in the 1990s due to xanomeline, an agonist initially developed for Alzheimer’s, showing unexpected antipsychotic effects.
- During that time, there were challenges in managing tolerability issues linked to the activation of peripheral mAChRs.
- Recent advancements in targeted ligands and combination treatments have improved the feasibility of mAChR activators as promising therapies for schizophrenia, with ongoing clinical development efforts.
Background: Recurrence after resection of metastatic sarcoma is common. The gangliosides GM2, GD2 and GD3 are strongly expressed across sarcoma subtypes. We hypothesised that generation of anti-ganglioside antibodies would control micrometastases and improve outcomes in sarcoma patients who were disease-free after metastasectomy.
View Article and Find Full Text PDFBackground: Impaired insight poses a challenge in the treatment of patients with schizophrenia because of its potential to jeopardize therapeutic engagement and medication adherence. This study explored how insight impairment, graded from none to extreme, is related to patient-reported mental health status, depression, and neurocognition in schizophrenia.
Methods: In a post hoc analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study (NCT00014001), insight was measured using the Positive and Negative Syndrome Scale (PANSS) Item G12 (lack of insight).